Schwarz C, Grehn C, Temming S, et al. - Researchers tested inhaled levofloxacin solution in terms of its efficacy in patients (n = 86) suffering from cystic fibrosis. They focused on following outcome parameters: alterations in %-predicted forced expiratory volume in one second (FEV ₁ ), body-mass index (BMI), and exacerbation rate. Patients who were administered levofloxacin inhalation solution twice daily 240 mg for at least 4 weeks, were analyzed via an intraindividual analysis. Alteration in FEV ₁ % predicted for the treatment span was +2.27% following 4 weeks. BMI did not alter for the overall group, but 1 year of treatment resulted in significant reduction in exacerbation rate when compared with that one year before initiation of inhaled levofloxacin. Findings demonstrate the potential of inhaled levofloxacin solution to bring about improvement in FEV ₁ as well as decrease in the number of bronchopulmonary exacerbations in cystic fibrosis patients.